Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
Input is information, insight, or advice given to us to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Therapeutic Area: Gastric or gastroesophageal junction (GEJ) adenocarcinoma Draft recommendations posted for stakeholder feedback: March 6, 2025 End of feedback period: March 21, 2025 Draft Recommendation
Therapeutic Area: Non-Small Cell Lung Cancer, neoadjuvant Draft recommendations posted for stakeholder feedback: March 6, 2025 End of feedback period: March 21, 2025 Draft Recommendation